Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI.
about
Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Adjusted Indirect Comparison U ...... ave Progressed after EGFR-TKI.
@en
Adjusted Indirect Comparison U ...... ave Progressed after EGFR-TKI.
@nl
type
label
Adjusted Indirect Comparison U ...... ave Progressed after EGFR-TKI.
@en
Adjusted Indirect Comparison U ...... ave Progressed after EGFR-TKI.
@nl
prefLabel
Adjusted Indirect Comparison U ...... ave Progressed after EGFR-TKI.
@en
Adjusted Indirect Comparison U ...... ave Progressed after EGFR-TKI.
@nl
P2093
P2860
P50
P1476
Adjusted Indirect Comparison U ...... ave Progressed after EGFR-TKI.
@en
P2093
Carolyn Bodnar
Christopher Hoyle
Frank Andersohn
Tetsuya Mitsudomi
P2860
P304
P356
10.1007/S40261-017-0611-3
P577
2018-04-01T00:00:00Z